Ekkehard Moessner

This inventor holds 100 USPTO granted patents and 109 published patent applications, plus 17 CIPO patents and 61 EPO patents, primarily in Antibody Engineering (CPC class C07K2317-92). Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, Engmab Sarl. Active years: 2011-2026.

USPTO Granted Patents = 100 (Patent Applications = 109)

% Patents Active = 84.0

CIPO Patents = 17 (Patent Applications = 43)

EPO Patents = 61 (Patent Applications = 123)

Average Co-Inventor Count = 7.1

ph-index = 17

Forward Citations = 971(Granted Patents)

Forward Citations (Not Self Cited) = 730(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Kruezlingen, CH (2019)
Kreuzlingen, CH (2011 - 2024)
Schlieren, CH (2020 - 2024)

Company Filing History:

52 out of 5,011

Hoffmann-La Roche Inc.

Bristol-Myers Squibb Compnay

Roche Sequencing Solutions, Inc.

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Tumor-Targeted Molecules

T Cell Activation

Anti-Human CD19

CD3 Binding

HER2 Antibodies

Tumor Necrosis Factor

Humanized Antibodies

Fc Variants

Cancer Treatment

Trispecific Antibodies

Antigen Binding Receptors

100 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735485 - BISPECIFIC ANTIGEN BINDING MOLECULES TARGETING OX40 AND FAP (2026-09-15),

2. 12637522 - MONOCLONAL ANTIBODIES AGAINST BCMA (2026-05-26),

3. 12600781 - TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES (2026-04-14),

4. 12590151 - ANTI-HUMAN CD19 ANTIBODIES WITH HIGH AFFINITY (2026-03-31),

5. 12473373 - BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND EGFRvIII (2025-11-18),

6. 12466889 - ANTI-HLA-G ANTIBODIES AND USE THEREOF (2025-11-11),

7. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

8. 12331134 - Trispecific antibodies specific for HER2 and a blood brain barrier receptor and methods of use (2025-06-17),

9. 12297263 - Humanized anti-Tau(PS422) antibodies and methods of use (2025-05-13),

10. 12291561 - Antigen binding receptors specific for mutated Fc domains (2025-05-06),

11. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),

12. 12258371 - Stabilized immunoglobulin domains (2025-03-25),

13. 12215155 - Antibodies binding to CD3 and CD19 (2025-02-04),

14. 12215152 - Humanized anti-human CD19 antibodies and methods of use (2025-02-04),

15. 12202870 - Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof (2025-01-21),

Title: The Innovative Mind of Ekkehard Moessner

Introduction: Ekkehard Moessner, located in Kreuzlingen, Switzerland, stands out as an accomplished inventor with a remarkable portfolio of 88 patents. His contributions to the field of biomedicine, particularly in antibody development, have made significant strides in advancing treatments for various diseases.

Latest Patents: Among his latest innovations are patents focusing on antibodies binding to CD3 and CD19. This invention relates to antibodies that not only activate T cells but also includes polynucleotides encoding such antibodies, along with vectors and host cells that utilize them. Furthermore, he has developed humanized anti-human CD19 antibodies. This antibody is characterized by specific amino acid sequences in its hypervariable regions and includes methods for its application in medical treatments.

Career Highlights: Throughout his illustrious career, Ekkehard Moessner has worked with prominent companies such as Hoffmann-La Roche Inc. and Roche Glycart AG. His expertise in the field has enabled him to lead projects that blend innovation with practical applications in health care, showcasing his dedication and skill as an inventor.

Collaborations: Ekkehard has collaborated with notable colleagues, including Christian Klein and Pablo Umana. Their collective efforts have contributed to advancing the understanding and capabilities of antibody therapies, significantly impacting the medical field.

Conclusion: Ekkehard Moessner’s impressive array of patents and collaborations marks him as a significant figure in the realm of pharmaceutical innovations. His work not only pushes the boundaries of science but also serves as a beacon of hope for patients requiring advanced therapeutic options.